8th DIA Cardiac Safety Workshop in Japan

Atsushi Sugiyama, MD, PHD

Professor and Chairman, Department of Pharmacology, Toho University Faculty of Medicine, Japan

Kyosuke Takeshita, MD, PHD

Department of Clinical Laboratory Medicine, Saitama Medical Center, Saitama Medical University, Japan

Börje C. Darpö, MD, PHD

Chief Scientific Officer, Cardiac Safety, Clario, Sweden

Replacing the Thorough QT study with Concentration-QTc analysis applied to First-in-Human studies – recent trends and experience from interactions with regulators

Kaori Shinagawa, MD, PHD

Senior Scientist for Clinical Medicine, Office of New Drug II, Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Current status and future perspective of clinical proarrhythmic risk assessment from a regulatory point of view

Jorg Taubel, MD, FFPM

Chief Executive Officer, Richmond Pharmacology, United Kingdom

Reasons why it is difficult to evaluate cardiac safety for antidiabetic drugs - Findings obtained in a type 1 diabetes study examining the effects of diet on normal and insulin-deficient subjects

Boaz Mendzelevski, MD

Consultant Cardiologist, Cardiac Safety Consultants Ltd., United Kingdom